The signal transducer and activator of transcription (STAT) 3 is essential for mediating signals from the receptors for a variety of cytokines and growth factors, including IL-6 and EGF, and from cytoplasmic tyrosine kinases. Upon stimulation, STAT3 is phosphorylated at Ser727 and Tyr705. However, the role of phosphorylation at Ser727, and the kinase pathways responsible for this phosphorylation in IL-6 signaling remain obscure. Here we show that IL-6 activates at least two distinct STAT3 serine kinase pathways and that an H7-sensitive pathway is dominant over a PD98059-sensitive one in HepG2 cells stimulated with a low concentration of IL-6. The analysis, using a series of chimeric receptors containing the extracellular domain of the G-CSF receptor, the truncated form of gp 130, and additional short peptides at the gp 130 carboxy-terminus, showed that the YXXQ motif of gp 130 was sucient for the H7-sensitive STAT3 Ser727 phosphorylation. This YXXQ-mediated pathway does not involve Erk, p38, JNK, or PKCd, and requires a site in the region from 533 to 711 of STAT3 for phosphorylation in vivo. Moreover, we show that Ser727 is required for full transcriptional activity of STAT3 for two dierent response elements. Thus, the YXXQ motif regulates STAT3 activities in two ways in response to even a low concentration of IL-6: it recruits STAT3 to the receptor for tyrosine phosphorylation, and activates an unidenti®ed H7-sensitive pathway leading to the serine phosphorylation of STAT3. Oncogene (2001) 20, 3464 ± 3474.
Introduction
The cytokine interleukin 6 (IL-6) and the rest of the IL-6 cytokine family, including leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), IL-11, and cardiotropin 1 (CT-1), exert their eects by activating multiple signaling pathways that are initiated by the shared gp 130 receptor molecule . Upon the ligation of cytokine receptors containing gp 130, the receptorassociated Janus kinases (JAKs), Jak1, Jak2, and Tyk2, become activated Stahl et al., 1994) . Once activated, JAKs phosphorylate the signal transducer gp 130 at key tyrosine residues, which in turn recruit STAT family proteins, especially STAT3 and STAT1 (Akira et al., 1994; Zhong et al., 1994; Fujitani et al., 1994; Darnell et al., 1994) , and other Src homology 2 domain (SH2)-containing proteins, including SHP-2 Stahl et al., 1995; Fukada et al., 1996) . These molecules recruited to the receptor, and other molecules recruited to the activated JAKs, such as Gab1 (Takahashi-Tezuka et al., 1998) , are then phosphorylated on tyrosine and activated by the Jaks. The activated molecules then activate gene expression or downstream signaling pathways, including the Ras/Raf/MAP kinase pathway and the phosphatidylinositol 3-kinase (PI3-kinase) pathway (Taniguchi, 1995) . Activated STAT3 induces the transcription of a variety of genes, including the acute phase reactants (Wegenka et al., 1993) , junB (Nakajima et al., 1993; Fujitani et al., 1994; Coer et al., 1995) , ICAM-1 , stat3 (Ichiba et al., 1998) , CDK inhibitor p19 INK4D (Narimatsu et al., 1997; O'Farrell et al., 2000) , c-myc (Kiuchi et al., 1999) , and the pim-1 and pim-2 gene family (Shirogane et al., 1999) . Activated STAT3 determines, in conjunction with other signaling pathways, the cell fate, that is, survival, growth, or dierentiation Nakajima et al., 1996; Minami et al., 1996; Fukada et al., 1996; Ihara et al., 1997) .
Serine/threonine kinase pathways are suspected of being involved in the Jak/Stat-mediated gene expression. Initially, it was shown that a serine/threonine kinase inhibitor, H-7, inhibits the IL-6-induced mRNA expression of the junB and Tis11 genes (Nakajima and Wall, 1991) and the transcription of a STAT3-driven reporter gene (Nakajima et al., 1993 (Nakajima et al., , 1995 . Partly consistent with this, serine phosphorylation of STAT3 in response to IL-6 and CNTF results in the generation of a slowly migrating form of STAT3, in an H-7-sensitive manner LuÈ tticken et al., 1995; Zhang et al., 1995) . Epidermal growth factor (EGF) also causes the phosphorylation of STAT3 at both Tyr705 and Ser727 Chung et al., 1997; Wen and Darnell, 1997) , and the latter is dependent on MEK/Erk kinase activity (Chung et al., 1997) . Although the phosphorylation of Ser727 by EGF and v-src (Bromberg et al., 1998) has been shown to be required for the full transcriptional activity of STAT3, the precise role of STAT3 phosphorylation on Ser727 and the identity and nature of the STAT3 kinases activated by the IL-6 cytokine family is not known. In fact, the kinase activities that cause STAT3 Ser727 phosphorylation, such as Erk (Chung et al., 1997; Jain et al., 1998) , PKCd (Jain et al., 1999) , and JNK (Lim and Cao, 1999) , have been shown to inhibit the activation of STAT3 and/or eventually inhibit the STAT3-dependent gene expression. In contrast, v-src induces Ser727 phosphorylation through multiple kinase pathways, that involve Ras, Rac, MKK4, p38, and JNK (Turkson et al., 1999) , and Ser727 phosphorylation is required for the full transcriptional activity of STAT3 (Bromberg et al., 1998; Turkson et al., 1999) .
In this study, we characterize the nature of the IL-6-induced H7-sensitive STAT3 kinase pathway and determine the region of gp 130 required for STAT3 Ser727 phosphorylation. We also elucidate the role of Ser727 in the transcriptional activity of STAT3. Our results indicate that, in addition to its originally de®ned role as a docking site for STAT3, the YXXQ motif in gp130 is also important in activating the H7-sensitive STAT3 kinase pathway, which is distinct from the Erk, p38, JNK, or PKCd pathways. Moreover, we show that phosphorylation of STAT3 on Ser727 is required for its full transcriptional activity for response elements containing two dierent STAT3-binding sites.
Results

Dominant role of an H7-sensitive STAT3 kinase pathway in HepG2 cells stimulated with low concentrations of IL-6
We ®rst tested whether the phosphorylation on Ser727 of STAT3 is primarily responsible for the mobility shift induced by IL-6/gp130 signals, as it is for the shift induced by EGF signals (Chung et al., 1997) . Wildtype STAT3 and two STAT3 mutants, one containing a Ser727 to alanine mutation (STAT3S727A) and the other containing a Tyr705 to Phe mutation (STAT3F, indicated as Y705F), were transiently expressed in 293T cells expressing the G-CSFR-gp130 chimeric receptor (293T-G277) and tested for their mobility shift after stimulation. The mobility shift was observed for wild-type STAT3 and STAT3F but not for STAT3S727A, and an antibody against the phosphorylated Ser727 of STAT3 (anti-P-Ser727) recognized only the shifted STAT3 bands (Figure 1a , lanes 1, 2, 5 and 6), indicating that phosphorylation on Ser727 was primarily responsible for the mobility shift associated with IL-6/gp130 signaling. Throughout this study, we Figure 1 The H7-sensitive STAT3 kinase pathway is dominant in HepG2 cells stimulated with a low dose of IL-6, but both the H7-sensitive and the PD98059-sensitive kinase pathways are codominant in HepG2 cells stimulated with IL-6 at 100 ng/ml. (a) 293T cells expressing the G-CSFR-gp130 chimeric receptors (293T-G277) were transiently transfected with expression vectors encoding HA-Stat3, HA-Stat3S727A, or HA-Stat3F and stimulated with G-CSF (100 ng/ml) for 30 min. Whole-cell extracts were immunoprecipitated with anti-HA Mab, separated on a 20-cm-long gel, and immunoblotted with anti-STAT3 antibody (upper panel) or anti-phospho (Ser727) STAT3 antibody (shown as a-P-S727, lower panel). (b) HepG2 cells cultured in DMEM containing 0.5% FCS for 20 h were pretreated with the indicated doses of H7, then stimulated with IL-6 (1 or 100 ng/ml) for 30 min. Immunoblotting (IB) was performed on whole-cell extracts (50 mg protein) using an anti-STAT3 or anti-P-Ser727 antibody. (c) Speci®city of the protein kinase inhibitors H7 and PD98059 on the STAT3 mobility shift induced by 1 ng/ml IL-6. HepG2 cells were preincubated for 30 min with no inhibitor, 100 mM H7, or the indicated doses of PD98059, then stimulated with IL-6 at 1 ng/ml for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift by immunoprecipitation (IP) and immunoblotting (IB) with anti-STAT3. (d) The STAT3 mobility shift caused by 100 ng/ml of IL-6 was completely inhibited only by the combination of H7 and PD98059. HepG2 cells that had been pretreated with 30 mM PD98059, 100 mM H7, or 30 mM PD98059 and 100 mM H7, were stimulated with IL-6 at 100 ng/ml for 30 min or left untreated. Whole-cell extracts were analysed for the STAT3 mobility shift due to Ser727 phosphorylation as in (b) used the two assays, the mobility shift assay and the immunoblot assay using the anti-P-Ser727 antibody, to detect the Ser727 phosphorylation of STAT3, because only the former assay allows an estimation of the proportion of STAT3 that is phosphorylated at Ser727 under conditions where a signi®cant portion of STAT3 is phosphorylated without stimulation.
As shown in Figure 1b , IL-6 induced Ser727 phosphorylation even at 1 ng/ml, and this phosphorylation was eectively inhibited by H7 with an IC 50 of 20 ± 50 mM. In comparison, the Ser727 phosphorylation that was induced by a high concentration of IL-6 (100 ng/ml) was resistant to 100 mM H7. At 1 ng/ml, IL-6 caused a mobility shift of approximately 70 ± 80% of the STAT3, and the mobility shift was totally inhibited by 100 mM H7, but was only mildly inhibited by a MEK inhibitor, PD98058, at 30 to 100 mM (Figure 1c) . At higher doses of IL-6, such as 100 ng/ ml, neither PD98059 nor H7 alone eectively inhibited the mobility shift, but the combination of PD98059 and H7 completely inhibited it (Figure 1d ). These results indicate that there are at least two STAT3 kinase pathways causing phosphorylation on Ser727 in HepG2 cells, an H7-sensitive and a PD98059-sensitive one, that the former pathway is dominant in HepG2 cells stimulated with low concentrations of IL-6, and that both pathways are co-dominant in HepG2 cells stimulated with 100 ng/ml IL-6.
Identification of the YXXQ motif in gp130 as a crucial site for activating the H7-sensitive STAT3 kinase pathway and the YSTV motif as a site for activating the PD98059-sensitive STAT3 kinase pathway
To determine the cytoplasmic regions of gp130 that are required for activation of the STAT3 kinase pathways, we ®rst used a series of 293T cell lines that express a chimeric receptor consisting of the extracellular domain of G-CSFR and the transmembrane and cytoplasmic domains of gp130 with progressive carboxy-terminal truncations. The cytoplasmic region, including the proximal 133 amino acid residues (Figure 2b , 293T-G277 and 293T-G133), was sucient to induce the STAT3 mobility shift, while the proximal 108 and 68 amino acid residues did not induce it (Figure 2b , 293T-G108 and 293T-G68), although the proximal region activates the associated Jak kinases and phosphorylates Gab1 (Takahashi-Tezuka et al., 1998) . Because the mobility shift caused by signals from the proximal 133 amino acid residues of gp130 was also inhibited only by the combination of H7 and PD98059 (data not shown) as in HepG2 cells, we proceeded to identify the sequence required for activating the two STAT3 kinase pathways within the region between amino acids 108 and 133 of gp130. For this purpose we made another series of 293T cell lines that expressed chimeric G108 receptors each carrying a 10 ± 12-residue-long peptide from this region at its carboxy terminus. Alternatively, some chimeric receptors carried a peptide comprising the motif from the region containing the ®fth tyrosine residue of gp130 or from the region containing Tyr440 of the interferon g receptor, which is essential for recruitment of STAT1 to the IFNg receptor (Greenlund et al., 1994) . These receptors are depicted schematically in Figure 2a . As shown in Figure 2b , Figure 2 The YXXQ motif is necessary and sucient for activation of the H7-sensitive STAT3 kinase pathway, while the YSTV motif is sucient for activation of the PD98059-sensitive kinase pathway. (a) Schematic structures of the chimeric receptors. Chimeric receptors were composed of the extracellular domain of the human G-CSF receptor and the transmembrane and membrane-proximal 108 amino acid residues with a peptide 10-to 12-residues long from the region between residues 108 and 133 in the cytoplasmic domain of human gp 130 (G108-Ys, G108-YSTV, G108-YRHQ). The G108-FSTV and G108-FRHQ receptors were mutants in which tyrosine (Y) residues in the YSTV and YRHQ peptides were replaced by phenylalanines (F). G108-YLPQ contained another YXXQ motif from the ®fth tyrosine residue (PKSYLPQYVR) of gp 130. G108-YDKP contained a motif that included Tyr440 of the IFN-g receptor chain. (b) A series of 293T cell lines expressing the full-length and variously truncated chimeric gp 130 receptors (293T-G277, 293T-G133, 293T-G108, and 293T-G68) (upper panel) and 293T cell lines expressing one of the above chimeric receptors (293T-G133, 293T-G108, 293T-G108-YS, 293T-G108-YSTV, 293T-G108-FSTV, 293T-G108-YRHQ, 293T-G108-FRHQ, 293T-G108-YLPQ, and 293T-G108-YDKP) (middle and lower panels) were either left unstimulated or stimulated with G-CSF for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift as in Figure 1c . (c) 293T cell lines with G108-YRHQ and G108-YSTV were pretreated with 100 mM H7 or 30 mM PD98059 for 30 min, then stimulated with G-CSF for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift as in Figure  1c only the 293T cell lines expressing the truncated GCSFR-gp130 chimeric receptors with either the intact YSTV (named 293T-G108-YSTV), the YRHQ (293T-G108-YRHQ), or the YLPQ (293T-G108-YLPQ) motif, but neither the 293T cell line expressing the truncated receptor with the YDKP motif from the interferon g receptor (293T-G108-YDKP) nor those expressing the receptors with the corresponding Tyr to Phe mutants (293T-G108-FSTV and 293T-G108-FRHQ), showed the induction of the mobility shift due to Ser727 phosphorylation. These results indicate a critical role for the YSTV and YXXQ motifs in activating STAT3 kinases, although the proportion of STAT3 showing the mobility shift was much lower in 293T cells than in HepG2 cells stimulated with IL-6, and the basal levels of Ser727 phosphorylation varied from cell line to cell line. We next tested the STAT3 kinase pathways derived from the two tyrosine motifs for their sensitivities to H7 and PD98059. As shown in Figure 2c , the STAT3 mobility shift mediated through the YSTV motif was eectively inhibited by PD98059, but not by H7, while that mediated through the YRHQ motif was eectively inhibited by H7, but only partially by PD98059. Similar results were obtained with 293T-G108-YLPQ cells (data not shown). The sensitivity of the YXXQ-mediated STAT3 kinase pathway to the two drugs is fully consistent with the result shown in Figure 1c . These results indicate that the two dierent tyrosine motifs are critical in activating the two distinct STAT3 kinase pathways. More importantly, these results indicate that the YXXQ motif has two roles: to recruit STAT3 through its SH2 domain and to activate the H7-sensitive STAT3 kinase pathway. It is noteworthy that the YDKP motif, which serves as a docking site for STAT1, did not activate the STAT3 kinase pathway, further suggesting the speci®c activation of the H7-sensitive STAT3 kinase pathway by the YXXQ motif.
The YXXQ-mediated H7-sensitive STAT3 kinase pathway is operative in a variety of gp130-signal responsive cell lines
We next tested whether the same YXXQ-mediated STAT3 kinase pathway functioned in cells other than 293T cells. We obtained stable transformants of HepG2 and NIH3T3 cells expressing the chimeric G108-YRHQ or a control receptor. In addition, we established three MH60 B cell hybridoma cell lines: one expressed G133; one expressed G133F2, with a Tyr to Phe mutation at the second tyrosine residue (in the YSTV motif); the third expressed G133F3, with a Tyr to Phe mutation at the third tyrosine residue (in the YRHQ motif) (see Figure 2a ). These lines were called MH60-G133, MH60-G133F2, and MH60-G133F3, respectively. Upon stimulation of the chimeric receptors, the ratio of shifted STAT3 increased in HepG2-G108-YRHQ and NIH3T3-G108-YRHQ cells, but not in HepG2-G108-FSTV or NIH3T3-G108-FRHQ cells ( Figure 3a) . The induced mobility shift in both HepG2-G108-YRHQ and NIH3T3-G108-YRHQ cells was inhibited by H7 (data not shown). Moreover, consistent with the failure of the G108-YDKP receptor to cause the STAT3 mobility shift, IFNg stimulation did not induce the STAT3 mobility shift in NIH3T3 (Figure 3a ) or HepG2 cells (data not shown), indicating a speci®c role for the YXXQ motif in the induction of the STAT3 Ser727 phosphorylation. Stimulation of gp130 with the intact YXXQ motif in two MH60 cell lines, MH60-G133 and MH60-G133F2, induced the STAT3 mobility shift (Figure 3b) . Surprisingly, stimulation of G133F3 receptors with the intact YSTV did not induce the STAT3 mobility shift in MH60-G133F3 cells, whereas IL-6 eectively caused the STAT3 mobility shift (Figure 3b ), indicating that the YSTV motif-mediated pathway either could not be activated or could not mediate Ser727 phosphorylation in MH60 cells. Consistent with this, the STAT3 mobility shift in parent MH60 cells induced Figure 3 The YXXQ-mediated STAT3 kinase pathway functions in various cell lines. (a) HepG2 cell lines expressing G108-YRHQ or G108-FSTV, and NIH3T3 cell lines expressing G108-YRHQ or G108-FRHQ were left unstimulated or stimulated with G-CSF or murine IFNg at 20 ng/ml (only for NIH3T3 cells) for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift using an anti-STAT3 antibody. (b) IL-6-dependent B cell hybridoma MH60 cell lines expressing G133, G133F2, or G133F3 receptors were deprived of IL-6 for 6 h, then either left unstimulated or stimulated with G-CSF or the indicated doses of IL-6 for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift using an anti-STAT3 antibody. (c) MH60 parental cells pretreated with the indicated doses of H7 for 30 min were stimulated with IL-6 at 100 ng/ml for 30 min. Whole-cell extracts were analysed for the STAT3 mobility shift using an anti-STAT3 antibody by 100 ng/ml IL-6 could be inhibited by H7 alone (Figure 3c ). These results indicate that the YXXQmediated H7-sensitve STAT3 kinase pathway functions in a variety of cell lines, and is the only kinase pathway responsible for STAT3 Ser727 phosphorylation in some cell types, such as B cell hybridoma cells. These results, together with the fact that only this H7-sensitive kinase pathway is active in HepG2 cells stimulated with low and physiological concentrations of IL-6, as shown in Figure 1 , suggest that this pathway is physiologically more important than the one mediated by the YSTV motif.
The YXXQ-mediated pathway is distinct from the PKCd, p38, JNK and Erk pathways Recently, several kinases activated by external signals and v-src have been reported to be involved in STAT3 Ser727 phosphorylation, including Erk for EGF (Chung et al., 1997) , PKCd for IL-6 (Jain et al., 1999) , and p38 and JNK for v-src (Turkson et al., 1999) . Therefore, we tested whether the YXXQmediated and H7-sensitive kinase pathway involved Erk, PKCd, p38, or JNK. The involvement of Erk was easily ruled out because low concentrations of IL-6 did not cause phosphorylation of Erk1/2 (data not shown), and because the Erk phosphorylation occurs mostly in a pYSTV motif-dependent manner . The kinase activity of PKCd and its association with STAT3 have been shown to increase in response to IL-6 in HepG2 cells (Jain et al., 1999) . However, in our hands repeated analysis using HepG2 cells did not show any association of PKCd with STAT3 in response to IL-6, even at 100 ng/ml; therefore, we used another way to assess the role of PKCd in the YXXQ motif-mediated STAT3 Ser727 phosphorylation. PKCd is an isotype of the PKC family that is activated by TPA as well as diacylglycerol, and can be depleted by long-term treatment with high concentrations of TPA (Szallasi et al., 1994) . As shown in Figure  4a , the amounts of PKCd in TPA-treated HepG2-G108-YRHQ cells (indicated by an arrow) decreased to a level near one-tenth of that in control HepG2-G108-YRHQ cells. However, the large decrease in the amount of PKCd in the TPA-treated cells did not cause any decrease in the induced STAT3 mobility shift, compared with that in the DMSO-treated cells, suggesting that PKCd is not involved in the YXXQmediated STAT3 kinase pathway. The activation of the p38 and JNK pathways was monitored by detecting the levels of activated p38 and JNK, which are phosphorylated at Thr180/Tyr182 and Thr183/ Tyr185, respectively. Gp130 stimulation did not cause an apparent increase in the levels of phospho-p38 (Figure 4b ) or phospho-JNK (data not shown) during the time course in either NIH3T3-G108-YRHQ ( Figure  4b ) or HepG2-G108-YRHQ (data not shown) cells, while TNFa treatment for 10 min caused a signi®cant increase in p38 phosphorylation in NIH3T3-G108-YHRQ cells. To further investigate whether p38 kinase is involved in the YXXQ-mediated STAT3 kinase activation, we tested whether a speci®c p38 kinase inhibitor, SB203580, could aect the Ser727 phosphorylation by the YXXQ-mediated kinase pathway. As shown in Figure 4b , 10 mM SB203580 did not inhibit the STAT3 mobility shift caused by the YXXQmediated pathway in NIH3T3-G108-YRHQ cells. Interestingly, TNFa, which activated p38 in NIH3T3 cells, did not cause the STAT3 mobility shift (Figure  4b) , further supporting the lack of involvement of p38 in the YXXQ-mediated STAT3 kinase activation. These results imply that the YXXQ-mediated and H7-sensitive kinase pathway does not use Erk, p38, JNK, or PKCd.
STAT3 Ser727 phosphorylation in vivo by the YXXQ-mediated pathway requires a region far upstream of the phosphorylation site
To obtain further insight into the characteristics of the YXXQ-mediated STAT3 kinase signal, we sought to determine the region of STAT3 required for in vivo Whole-cell extracts were assayed for phospho-p38 and total p38 by immunoblot analysis using an anti-phospho-p38 and an anti-p38 antibody. NIH3T3-G108-YRHQ cells were pretreated for 30 min with either no addition or 10 mM SB203580, then either left unstimulated or stimulated with G-CSF or TNFa (20 ng/ml) for 30 min. Wholecell extracts were assayed for the STAT3 mobility shift using an anti-STAT3 antibody STAT3 kinase activation by the YXXQ motif in gp 130 K Abe et al phosphorylation. A series of fusion proteins of GST and various amino-terminally truncated STAT3 molecules, depicted in Figure 5a , were expressed in the NIH3T3-G108-YRHQ cells and used as substrates for in vivo phosphorylation by the YXXQ-mediated STAT3 kinase pathway. The YXXQ-mediated pathway (Figure 5b , lanes 1 ± 6) phosphorylated GST-STAT3 fusion proteins containing the region extending from at least amino-acid 533 to the carboxyl terminus of STAT3. However, the pathway did not increase the phosphorylation level of GST-STAT3 7117770 (lanes 7 and 8), whereas TPA eectively induced phosphorylation at Ser727 in GST-STAT3 7107770 and caused a mobility shift of virtually all of the GST-STAT3 7107770 (Figure 5b , lanes 9 and 10, upper phosphorylated bands and lower unphosphorylated bands are indicated by two asterisks and one asterisk, respectively). These results suggest that a region from residues 533 to 711 of STAT3 is required for sucient phosphorylation of Ser727 by the YXXQ-mediated STAT3 kinase, and this region may be a docking site for the STAT3 kinase.
STAT3 Ser727 is required for the full STAT3-dependent transcription activity
The role of the serine phosphorylation of STAT3 in transcriptional activity has only been suggested by indirect evidence. Wen et al. (1995) reported that a mutant STAT3 containing the substitution of Ser727 with Ala reduced the STAT3-dependent activation of a reporter gene in response to EGF. Bromberg et al. (1998) reported that the same mutant STAT3 (STAT3-S727A) suppressed the number of v-src-transformed NIH3T3 colonies in soft agar. These results suggest that the phosphorylation of STAT3 on Ser727 enhances STAT3's transcriptional activity in some instances, although there are con¯icting reports showing a negative role for STAT3 Ser727 phosphorylation in transcription (Chung et al., 1997; Jain et al., 1998; Sengupta et al., 1998) . One implication of all of these observations is that unidenti®ed mechanisms may aect the overall transcriptional activity of STAT3. To investigate the role of STAT3 Ser727 phosphorylation in IL-6/gp130 signaling, we used a system intended to detect the activity of exogenously expressed STAT3 without signi®cantly activating the SHP2/Ras/Raf/ MAPK pathway or endogenous STAT3. HepG2 cells were transfected with STAT3-responsive reporter genes containing either multimerized acute-phase response element, APRE, or the junB IL-6 response element, JRE-IL6 (Nakajima et al., 1993 (Nakajima et al., , 1995 , and an expression vector encoding either wild-type STAT3 or mutant STAT3S727A, together with an expression vector encoding the G-CSFR-gp130 chimeric receptor truncated at the 108th residue of the cytoplasmic domain of gp130 (G-108). Stimulation of the truncated gp130 receptor induced the tyrosine phosphorylation of the over-expressed STAT3 and STAT3S727A at a much lower level than that induced by intact gp130 (data not shown). The exogenous STAT3 molecules were phosphorylated on Ser727, at levels ranging from 20 to 30% of the total exogenously expressed STAT3 (data not shown) in HepG2 cells under the conditions used here. Note that the phosphorylation level of STAT3 did not change in response to stimulation of the truncated receptor (Figure 6b , lanes 1 and 2) and that the expression levels of the wild-type STAT3 and STAT3S727A were comparable ( Figure 6b , lanes 1 ± 4). Under these conditions, as shown in Figure 6a , stimulation of the truncated receptor weakly activated the reporter gene driven by APRE (around 10 ± 15-fold above baseline), compared with the levels stimulated by IL-6 (around 150 ± 200-fold above baseline, data not shown). In the presence of exogenous wild-type STAT3, stimulation of the receptor induced an approximately 150-fold increase in the expression of the APRE-driven reporter gene (Figure 6a ). On the other hand, activation of the STAT3S727A mutant by the truncated receptor caused only a 30 ± 50-fold activation of the same reporter gene, suggesting a role Figure 5 The region of STAT3 required for Ser727 phosphorylation by the YXXQ-mediated STAT3 kinase pathway in vivo.
(a) A schematic representation of the GST-STAT3 truncation mutants used for the in vivo phosphorylation study is shown. (b) NIH3T3-G108-YRHQ cells (3610 6 cells) were transfected with 20 mg of one of the series of pEFGST-STAT3 plasmids shown above, cultured in DMEM containing 0.5% FCS for approximately 36 h, and left unstimulated or stimulated with G-CSF or TPA at the indicated concentrations for 30 min. Whole-cell extracts were immunoprecipitated (IP) with an anti-GST antibody, followed by separation on a 4 ± 20% gradient gel and immunoblot analysis (IB) using an anti-STAT3 and an anti-PSer727 antibody. Two asterisks and one asterisk indicate the shifted, Ser727-phosphorylated GST-STAT3 7117770 and the unphosphorylated form, respectively for Ser727 phosphorylation in conferring the full transcriptional activity on STAT3 (Figure 6a) . Similar results were obtained with the other reporter gene, driven by JRE-IL6, which contains a low-anity STAT3-binding site and an atypical CRE . The basal expression level driven by JRE-IL6, however, was much higher and the fold activation of the reporter gene was much lower, compared with those seen with the APRE-driven Luc reporter ( Figure  6a ). Given that the expression levels of the transfected wild-type STAT3 and STAT3S727A were comparable (see Figure 6b) , and that the substitution of Ser727 with Ala does not reduce the DNA-binding activity of the STAT3 dimer , we estimated the transcriptional activity of STAT3S727A to be less than one fourth that of the wild-type STAT3 for both types of DNA response elements.
Discussion
STAT3 plays important roles in regulating multiple and diverse cellular processes initiated by a variety of extracellular signals, including the IL-6 family of cytokines, growth factors such as EGF and HGF, and intracellular signals including oncogenic v-src. Although a number of STAT3 target genes have been reported, the mechanisms by which STAT3 activity is regulated through post-translational modi®cation, e.g., phosphorylation on serine, or through interaction with other proteins are still largely unknown, as are the mechanisms STAT3 uses to exert its transcriptional activity. In this paper, we focused on the nature of the kinase pathways leading to the phosphorylation of STAT3 on serine in response to IL-6/gp130 signals and the role of the STAT3 serine phosphorylation. Here, we demonstrate that IL-6 activates at least two distinct STAT3 kinase pathways causing Ser727 phosphorylation, which are activated through two dierent tyrosine motifs; one is eciently activated through the YXXQ motif in response to low concentrations of IL-6 and the other is activated through the YSTV motif with higher concentrations of IL-6. In some cells, only the former H7-sensitive STAT3 kinase pathway is activated, as seen in an IL-6-dependent B cell hybridoma cell line (Figure 3) . Together with the result showing that Ser727 phosphorylation enhances the transcriptional activity of STAT3 in IL-6/gp130 signaling (Figure 6a ), this study indicated that the YXXQ motif in gp130, a known docking site for STAT3, has another important role ± the activation of an unidenti®ed H7-sensitive kinase pathway that leads to the phosphorylation of STAT3 on Ser727, thereby enhancing the transcriptional activity of the STAT3 dimer in the nucleus. The other serine kinase pathway seemed to involve the Ras/ Raf/MEK/Erk pathway based on the following evidence: (1) the pathway is activated through the YSTV motif, which is a known docking site for SHP-2 and is important for activation of the Ras/Raf/MEK/ Erk pathway Fukada et al., 1996) ; (2) the phosphorylation of STAT3 Ser727 by this pathway was inhibited by the MEK inhibitor PD98059 ( Figure 2c) ; and (3) the STAT3 kinase activity caused by this pathway was well correlated with the level of Erk1/2 activation (unpublished observation).
The YXXQ motif is present in a variety of signaltransducing receptors, including gp130, LIF-R, G-CSFR, leptin-R, and IL10-R, all of which are known to activate STAT3 Stahl et al., 1995) . Therefore, it is likely that these receptor systems also activate the H7-sensitive kinase pathway. Although at present we do not know how the YXXQ (108), and 10 mg of either pEF-FLAGStat3 wild-type or pEF-FLAG-Stat3S727A. Transfected cells were cultured in DMEM containing 10% FCS for approximately 36 h and stimulated with G-CSF for 30 min. The amounts of whole-cell extract used for immunoprecipitation were adjusted according to the b-galactosidase activity. Immunoprecipitates brought down by the anti-FLAG (M2) monoclonal antibody were assayed for the amount and the proportion of phosphorylation on Ser727 as assessed by immunoblot analysis using an anti-STAT3 antibody and an anti-P-Ser727 antibody. About 20 ± 30% of exogenously expressed STAT3 in HepG2 cells was phosphorylated on Ser727 without stimulation under the conditions used here (see text)
STAT3 kinase activation by the YXXQ motif in gp 130 K Abe et al motif is involved in activation of the H7-sensitive kinase pathway, we speculate that an adapter molecule or an unidenti®ed kinase molecule capable of initiating the H7-sensitive kinase pathway can recognize the same docking site as does STAT3. However, it is also possible that some molecule able to initiate the STAT3 kinase pathway is recruited to the receptor through its interactions with STAT3. As a precedent, the p85 subunit of PI3-kinase has been shown to be activated in the interferon system in a STAT3-dependent manner (Uddin et al., 1997) . In the IL-6/gp130 system, however, PI3 kinase is activated in a Gab1-and SHP-2-dependent manner, and the stimulation-induced association of PI3 kinase or SHP-2 with Gab1 requires the YSTV motif (Takahashi-Tezuka et al., 1998) . Recently, phosphotyrosine motifs other than YXXQ, such as the YVNV motif in the HGF receptor and the YXXC motif in the G-CSF receptor, have been reported to serve as docking sites for STAT3 (Boccaccio et al., 1998; Chakraborty et al., 1999) . Investigating whether such motifs can also activate the H7-sensitive kinase pathway should provide insight into the nature of the initiator of this kinase pathway. It will also be intriguing to test whether the situation we report here, where phosphotyrosine motifs are involved both in recruiting a STAT molecule and in activating a kinase pathway leading to phosphorylation on serine of the same STAT molecule, may apply to other members of the STAT family, especially STAT1, STAT4, and STAT5, which are also known to be phosphorylated on a serine residue (Beadling et al., 1996; Cho et al., 1996; Wen et al., 1995) . Clearly, more studies will be required to resolve these questions. IFNg causes phosphorylation on Ser727 of STAT1 in the cytoplasm with slow kinetics (Zhu et al., 1997) . Consistent with the observation that the YDKP motif, which serves as a docking site for STAT1 in the IFNg receptor system, did not induce STAT3 Ser727 phosphorylation, IFNg at 20 ng/ml did not induce the phosphorylation of STAT3 on Ser727 in NIH3T3 (Figure 4a ) or HepG2 (data not shown) cells, indicating that dierent kinase pathways are responsible for STAT1 and STAT3 Ser727 phosphorylation. Although several kinases, including Erk, p38, JNK, and PKCd have been shown to induce STAT3 phosphorylation on Ser727, directly or indirectly (Chung et al., 1997; Jain et al., 1998 Jain et al., , 1999 Lim and Cao, 1999; Sengupta et al., 1998) , none of them is involved in the YXXQ-mediated H7-sensitive kinase pathway. TPA, which activates PKC and Erk, eectively phosphorylated Ser727 of STAT3 in vivo in the context of a GST-fusion protein containing the short region of STAT3 extending from residue 711 to 770, while the YXXQ-mediated kinase pathway required a larger portion of STAT3 to phosphorylate Ser727. This observation was consistent with the lack of involvement of Erk MAP kinase in the YXXQmediated kinase pathway and suggests that a docking site for the so-far poorly characterized STAT3 kinase may reside in the amino-terminally extended region from residues 533 to 711.
Recently, Yokogami et al. (2000) reported that mTOR is activated by CNTF and is involved in the phosphorylation of STAT3 on Ser727 in response to CNTF. However, it is unlikely that mTOR is involved in the YXXQ-mediated H7-sensitive STAT kinase pathway, because rapamycin at 10 mM had no eect on the STAT3 mobility shift induced by the YXXQmediated pathway (unpublished observation, Abe et al., 2001) . Very recently, Schuringa et al. (2000) reported that stimulation of HepG2 cells with IL-6 at 25 ng/ml causes a weak increase in SEK-1/MKK4 Thr223 phosphorylation, and that the over-expression of any of the following dominant-negative mutants ± SEK-1/MKK4(A-L), Vav-C, Rac N17, or MEKK1d(K432M) ± inhibits the phosphorylation of co-transfected STAT3 on Ser727. Although we did not detect MKK4 activation in HepG2 cells stimulated with IL-6 at any concentration tested or in stimulated-NIH3T3-G108-YRHQ cells (unpublished observation), it is still possible that a pathway involving a kinase that is very similar to SEK-1/MKK4 and that is inhibited by its dominant-negative mutant, SEK-1/MKK4(A-L), might be activated through the YXXQ motif and be responsible for activation of the H7-sensitive STAT3 kinase pathway.
In contrast to the established role of Ser727 phosphorylation of STAT1 Bromberg et al., 1996; Horvath and Darnell, 1996; , the role of STAT3 Ser727 phosphorylation is still obscure. Because there are no available cell lines or primary cells defective in STAT3 expression, it has been dicult to evaluate the role of phosphoserine(s) in STAT3 transcriptional activity. In fact, several conicting results concerning the role of STAT3 serine phosphorylation have been reported. Moreover, in a common transfection assay using HepG2 cells, overexpressed STAT3S727A does not function as a dominant-negative mutant (data not shown). In this study, therefore, we used a speci®c transient transfection assay with the G108 chimeric receptor to detect, for the most part, the transcriptional activity of exogenously overexpressed STAT3. Although the chimeric receptors containing gp130 truncated at the 108th amino acid activated the STAT3-dependent transcription of the reporter genes ineciently, they activated signi®cant amounts of STAT3 when STAT3 was overexpressed, as shown in Figure 6a . Using this system, STAT3 Ser727 was found to be required for the full transcriptional activity of STAT3 for both APRE and JRE-IL6, supporting the notion that phosphorylation on Ser727 enhances the transcriptional activity of STAT3 in response to IL-6/gp130 signals. Recently, it was reported that both the STAT3 mutant STAT3S727A and STAT3b, a splicing variant of STAT3 lacking the carboxy-terminal region including Ser727, are as active as full-length STAT3 (STAT3a), when acting with c-Jun on a DNA target from the promoter region of the rat a2 macroglobulin (Schaefer et al., 1999) . Therefore, it is likely that c-Jun complexed with STAT3, but not the CRE-like site binding protein(s) complexed with STAT3 in the case of the JRE-IL6 of the junB promoter , may have another way of rendering the DNAbinding complex transcriptionally active that does not require phosphorylated Ser727. Regarding the targets for the inhibitor H7, we have preliminary data showing that there must be another target for H7 in addition to the one shown in this paper, because H7 can inhibit STAT3-dependent transcription even at low concentrations that do not signi®cantly aect the Ser727 phosphorylation (Sekimoto and Nakajima, 2001, unpublished observation) . Thus, a comprehensive understanding of the regulatory mechanisms underlying STAT3-mediated transcription will require extensive investigation in the future.
Materials and methods
Reagents and antibodies
The sources for some of the materials used were as follows: protein kinase inhibitor H7 (1-[5-isoquinolinesulfonyl]-2-methylpiperazine), p38 MAPK inhibitor SB203580, and MEK inhibitor PD98059, were from CalbiochemNovabiochem Corp. (La Jolla, CA, USA); 12-O-tetradecanoyl phorbol-13-acetate (TPA) was from SigmaAldrich (Saint Louis, MO, USA). Recombinant human IL-6 and recombinant human G-CSF were gifts from Ajinomoto Research Institute and Chugai Pharmaceutics, respectively. Recombinant murine IFNg, human IFNg, and murine TNFa were obtained from PeproTech EC LTD (London, UK). Rabbit anti-Stat3 serum was described previously . Anti-phospho (S727) STAT3, anti-phospho (Thr202/Tyr204) MAPK, anti-MAPK, anti-phospho-p38, anti-phospho-SAPK/JNK, anti-SAPK/JNK, and anti-phospho-MKK4 antibodies were from New England BioLabs Inc. (Beverly, MA, USA). Anti-PKCd antibody, anti-c-Myc Mab, 9E10, and anti-p38 antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anti-GST antibody and anti-phosphotyrosine Mab 4G10 were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Antihuman G-CSFR Mab was from BD PharMingen (San Diego, CA, USA). Anti-FLAG Mab (M2) was from Sigma-Aldrich (Saint Louis, MO, USA).
Plasmids
Chimeric receptors An expression vector pCDNA-G108MycHis, which encodes the extracellular domain of G-CSFR, the transmembrane and cytoplasmic domains of human gp130 truncated at the 108th amino-acid residue with an EcoRV site, and a Myc and His6 tag at the carboxylterminus, was constructed as follows. An XhoI-EcoRI cDNA fragment encoding most of the extracellular domain of the G-CSFR was subcloned into the pcDNA3.1Myc-His vector (Invitrogen). Then, to make pcDNA-G108, a polymerase chain reaction (PCR) product encoding the transmembrane and cytoplasmic domains of human gp130, truncated at the 108th amino-acid residue with an EcoRI site at the 5' end and EcoRV and EcoRI sites at the 3' end was ligated into the above construct. The primers used to amplify the G108 fragment by PCR were the G-CSFR 5' primer, 5'-TCCTCACCCTGATGACCTTGA-3', and the gp108EcoRV, EcoRI primer, 5'-TTGAATTCGATATCGA-TTCATTTTCATCACTGCTAG-3'. To make the pcDNA-G108-YSMyc-His, pcDNA-G108-YSTVMyc-His, pcDNA-G108-FSTVMyc-His, pcDNA-G108-YRHQMyc-His, pc-DNA-G108-FRHQMyc-His, pcDNA-G108-YLPQMyc-His, and pcDNA-G108-YDKPMyc-His vectors, the following oligonucleotides and their corresponding complementary oligonucleotides were annealed and inserted at the EcoRV and HindIII sites of the pcDNA-G-108MycHis construct. YS, 5'-ATCACAAAACACTTCGAGCACTGTCCAGTATTCT-3'; YSTV, 5'-AAGCACTGTCCAGTATTCTACCGTGGTAC-ACAGTGGC-3'; FSTV, 5'-AAGCACTGTCCAGTTCTTC-TACCGTGGTACACAGTGGC-3'; YRHQ, 5'-AGTGGTA-CACAGTGGCTACAGACACCAAGTTCCGTCAGTC-3'; FRHQ;
5'-AGTGGTACACAGTGGCTTCAGACACCA-AGTTCCGTCAGTC-3'; YLPQ; 5'-ACCTAAAAGTTACT-TACCACAGACTGTACGG-3'; YDKP, 5'-ATCCTTTGGT-TATGATAAACCACATGTGCTA-3'.
Epitope-tagged Stat3 and GST-STAT3 expression vectors pEFHAStat3 and pEFHAStat3F were described previously . pEFHAStat3S727A was made by introducing a point mutation at Ser727 to change it to Ala. For some expression vectors, a FLAG tag was added at the amino-terminus of STAT3 by introducing an annealed oligonucleotide encoding the FLAG peptide in pBluescriptII and transferring the tagged Stat3 to pEF-BOS (a gift from Dr S Nagata). A series of constructs expressing GST-STAT3 fusion proteins in mammalian cells ± pEF-GST-STAT3 1587770 , pEF-GST-STAT3 4507770 , pEF-GST-STAT3 5337770 , and pEFGST-STAT3 7117770 ± were made by subcloning a series of STAT3 fragments into pEF-GST.
Cells and establishment of stable transfectants
HepG2, 293T, NIH3T3, and their derivative cell lines were grown in Dulbecco's modi®ed Eagle's medium (DMEM, GIBCO ± BRL) supplemented with 10% fetal calf serum (FCS; Intergen, Purchase, NY, USA) and antibiotics (100 U/ ml penicillin and 100 mg/ml streptomycin). An IL-6-dependent B cell hybridoma cell line, MH60 (Matsuda et al., 1988) , and its derivative cell lines were grown in RPMI (GIBCO ± BRL) with 10% FCS, antibiotics, and 1 ng/ml human recombinant IL-6. 293T-based cell lines expressing one of a series of G-CSFR-gp130 chimeric receptors, including 293T-G277, 293T-G133, 293T-G108, and 293T-G108 were described previously (Takahashi-Tezuka et al., 1998) . To make stable MH60 cell lines expressing one of the chimeric receptors, MH60-G133, G133F2, or G133F3, 30 mg of each expression vector along with 3 mg of pBSpacDP were transfected by electroporation, and the transformants were selected with puromycin (2.5 mg/ml). The transformants expressing similar levels of the chimeric receptors were chosen using a cell sorter (FACScan; Becton Dickinson) and the anti-human G-CSFR antibody. 293T-based cell lines expressing one of a series of G108 constructs plus a short peptide: 293T-G108-YS, 293T-G108-YSTV, 293T-G108-FSTV, 293T-G108-YRHQ, 293T-G108-FRHQ, 293T-G108-YLPQ, and 293T-G108-YDKP, were established by cotransfecting 293T cells with pBSpacDP and one of the pcDNAG108MycHis expression plasmids. Transfectants were tested for their expression levels of the chimeric receptors by immunoblotting with the anti-c-Myc antibody, and the levels were con®rmed by¯ow cytometry analysis using the Mab against human G-CSFR. To establish HepG2 and NIH3T3 cell lines expressing the chimeric receptors, retrovirus-mediated gene transfer was used, according to the instructions provided by G Nolan at Stanford University. First, the retroviral vectors, encoding G108-YSTV, G108-FSTV, G108-YRHQ, and G108-FRHQ, respectively, were constructed in pMX (a gift from Dr T Kitamura, Tokyo University) containing a hygromycin-resistance gene driven by the phosphoglycerokinase promoter (designated pMX-pgkHyg). The retroviruses were prepared from the supernatants of Phoenix producer cells (a generous gift from Dr G Nolan at Stanford University) that had been transiently transfected with the above retroviral vectors, and were then infected into HepG2 and NIH3T3 cells. Transfectants were tested for their expression levels of the chimeric receptors by immunoblot assays of the whole-cell lysates with an anti-c-Myc antibody.
Immunoprecipitation and immunoblot analysis
To detect changes in the levels of STAT3 serine phosphorylation or mobility shift in the HepG2, 293T, HepG2, and NIH3T3 cell lines expressing the chimeric receptors, the cells were cultured in medium with 0.5% FCS for 24 h before treatment with IL-6 at the indicated concentrations, IFNg at 20 ng/ml, or G-CSF at 100 ng/ml. MH60-derived cell lines were deprived of IL-6 for 6 h before stimulation. Inhibitors were added 30 min prior to cell stimulation. Whole-cell extracts were prepared by lysing the cells in ice-cold lysis buer (50 mM HEPES pH 7.5, 1% NP-40, 250 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.1 mM sodium vanadate, 0.1 mM PMSF, 10 mg/ml leupeptin and aprotinin, and 1 mM sodium¯uoride) with vigorous vortexing. Extracts were cleared by centrifugation at 14 000 g at 48C for 10 min. To detect the mobility shift of STAT3, anti-Stat3-immunoprecipitates were separated on 20-cm long, 7.5% SDSpolyacrylamide gels by electrophoresis, transferred to PVDF membranes, and probed with antibodies to Stat3. Signals were detected with the ECL system (Amersham Pharmacia). Immunoblot analysis using an anti-P-S727 antibody was also performed. In some experiments, immunoprecipitates were separated on short gels.
Transient transfection and luciferase assay
For transient transfection to detect the transcriptional activities of the exogenously expressed STAT3, HepG2 cells were transfected with 1.2 mg of a 46APRE Luc or a 36JRE-IL6 Luc reporter gene, 1 mg of pEF-LacZ, 2.5 mg of pEF-G-CSFR-gp130(108), and 2.5 mg of pEF-BOS, pEFFLAGStat3 or pEF-FLAGStat3S727A, using the calcium phosphate precipitation method. The transfected cells were re-fed with DMEM containing 10% FCS and stimulated with 100 ng/ml G-CSF for 6 h. Cell lysates were harvested and assayed for luciferase and b-galactosidase activities as previously described .
